AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
Related Articles
Health plans, advocacy groups descend on DC ahead of Medicaid markup hearing
It’s markup week in the House. | It’s markup week in the House for the ‘one big, beautiful bill.’ Lawmakers will debate significant programmatic changes…
Rademikibart Improves Lung Function in Patients with Asthma within 24 Hours
This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.
Governors Address Behavioral Health Needs for 2025
Across the country, governors continue to make behavioral health a priority—using their State of the State, budget, and inaugural addresses to highlight investments in behavioral…
Access to diabetes care in lower-income countries still lags for children, despite pharma efforts
Access to diabetes care in lower-income countries still lags for children, despite efforts from insulin makers.
Scribe
Welcome to Scribe, your new assistant for clinical note-taking! This HIPAA compliant AI-powered tool listens to your patient visits and creates an EHR-ready summary. Say…
The companies pushing MRI scans and blood tests for longevity
Longevity startups have become trendy in digital health, drawing attention from celebrity and established investors.
Genomic impacts of non-coding DNA variants : Cell Press
A joint collection highlighting recent papers that explore the many ways in which the effects of non-coding genetic variation can impact individuals.
FDA will limit Covid vaccines to people over 65 or at high risk of serious illness, leaders say
The FDA announced it will limit access to Covid-19 vaccines going forward to people 65 and older and others at high risk of serious illness
Tumor Dosimetry in PSMA Therapy: A VISION Substudy Analysis – Ken Herrmann
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…
Pharmalittle: We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more
Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy